Securities Class Action Lawsuit Filed Against Nuvelo, Inc.證券集體訴訟控告nuvelo公司
A class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all securities purchasers of Nuvelo, Inc. from January 5, 2006 through December 8, 2006, alleges Nuvelo and certain of its officers and directors with violations of the Securities Exchange Act of 1934.集體訴訟已提交了在美國地區法院為紐約南區代表所有證券的購買者nuvelo ，公司從2006年1月5日通過2006年12月8日，指稱nuvelo和其某些人員和董事違反了1934年證券交易法案。
Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Schiffrin Barroway Topaz & Kessler.原告要求收回損害賠償的名義階層成員和代表律師事務所schiffrin barroway黃玉＆凱斯勒。
The Complaint alleges that the Company failed to disclose and misrepresented the following material adverse facts which were known to defendants or recklessly disregarded by them: (1) that the clinical trial information regarding multiple alfimeprase studies was inaccurate; (2) specifically, clinical data from testing failed to show that alfimeprase, when administered through a catheter, could dissolve blood clots; (3) that no reliable data existed to show that alfimeprase would meet the high standards for efficacy for FDA approval; (4) that such information, as described above, was known to Defendants as early as December 2004, when Amgen discontinued its investment in alfimeprase; and (5) that, as a result of the above, the Company’s statements concerning alfimeprase and its clinical trials were lacking in any reasonable basis when made.投訴指稱該公司沒有透露和歪曲了以下重大不利的事實，被稱為被告人或罔顧實情地無視他們： （ 1 ）臨床試驗的資料，就多alfimeprase的研究是不準確的; （ 2 ）具體來說，從臨床資料測試失敗顯示alfimeprase ，當管理，通過導管，可以解散血液凝塊; （ 3 ）沒有可靠的數據的存在是為了表明， alfimeprase將滿足高標準的療效為FDA的批准; （ 4 ）這些資料，描述以上，被稱為向被告早在2004年12月，當安進中止其投資在alfimeprase ;和（ 5 ） ，由於上述情況，該公司的聲明，關於alfimeprase及其臨床試驗，缺乏任何合理的基礎當作出。
If you are a member of the class described above, you may, not later than April 10, 2007, move the Court to serve as lead plaintiff of the class, if you so choose.如果您是會員的階級上文所述，你可以，不得遲於2007年4月10日，動議法院充當導致原告的階級，如果您選擇。 A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.帶頭原告是代表黨的行為，代表其他階層成員在指揮訴訟。
You may also like to read您也可以想讀
- Securities Class Action Lawsuit Filed Against Nuvelo, Inc.證券集體訴訟控告nuvelo公司
- Securities Class Action Lawsuit Filed Against Nuvelo, Inc.證券集體訴訟控告nuvelo公司
- Securities Class Action Lawsuit Against Monster Worldwide Inc.證券集體訴訟的Monster Worldwide公司
- Securities Class Action Lawsuit Filed Against Coast Financial Holdings, Inc.證券集體訴訟控告海岸的金融控股公司
- Securities Class Action Lawsuit Filed Against Jabil Circuit Inc.證券集體訴訟控告Jabil公司電路公司
- Xerium Technologies in Security Class Action Lawsuit xerium技術在安全集體訴訟
- Amgen, Inc. in Securities Class Action Lawsuit Amgen的，公司在證券集體訴訟
- Securities Class Action Lawsuit Against Globalstar, Inc.證券集體訴訟Globalstar公司，公司
- Securities Class Action Lawsuit Filed Against Brooks Automation, Inc.證券集體訴訟控告布魯克斯自動化公司
- Securities Class Action Lawsuit Against New Century Financial Corp.證券集體訴訟新世紀金融公司
